| P2093 | author name string | Fei Mao | |
| | Jian Lu | |
| | Jian Li | |
| | Jiaying Wang | |
| | Lei Fan | |
| | Xu Shen | |
| | Jin Zhu | |
| | Wenwen Liu | |
| | Xiaokang Li | |
| | Xiaoxia Qiu | |
| | Baoli Li | |
| | Yixiang Xu | |
| P2860 | cites work | Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments | Q24599152 |
| | The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 |
| | Alzheimer's disease: genes, proteins, and therapy | Q28131806 |
| | mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease | Q28256208 |
| | Autophagy: renovation of cells and tissues | Q29547206 |
| | Autophagy: process and function | Q29547296 |
| | p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death | Q29547297 |
| | Autophagy gone awry in neurodegenerative diseases | Q29614849 |
| | The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics | Q29614972 |
| | Alzheimer's disease | Q29616743 |
| | Tau-mediated neurodegeneration in Alzheimer's disease and related disorders | Q29618148 |
| | Amyloid deposition as the central event in the aetiology of Alzheimer's disease | Q29619450 |
| | Near-infrared fluorescent probes for imaging of amyloid plaques in Alzheimer׳s disease | Q31025427 |
| | Alzheimer's disease drug-development pipeline: few candidates, frequent failures | Q33892815 |
| | Drug candidates in clinical trials for Alzheimer's disease | Q33916749 |
| | Astrocyte senescence as a component of Alzheimer's disease | Q34416365 |
| | New uses for old drugs | Q34661227 |
| | Autophagy failure in Alzheimer's disease--locating the primary defect | Q34987827 |
| | Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective | Q36568119 |
| | A century of Alzheimer's disease | Q36643414 |
| | Going forward with genetics: recent technological advances and forward genetics in mice. | Q36817566 |
| | Abeta-degrading enzymes in Alzheimer's disease. | Q37118130 |
| | Microtubule assembly, organization and dynamics in axons and dendrites | Q37450792 |
| | Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease | Q37519725 |
| | Control of autophagy as a therapy for neurodegenerative disease | Q37970303 |
| | Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system | Q38093006 |
| | Role of autophagy in the pathogenesis of Alzheimer disease. | Q38688571 |
| | Autophagy and Alzheimer's Disease | Q38853431 |
| | The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients | Q39222469 |
| | A reporter cell system to monitor autophagy based on p62/SQSTM1. | Q39688848 |
| | Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients | Q40664845 |
| | A phase 3 trial of semagacestat for treatment of Alzheimer's disease | Q42710153 |
| | Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease | Q44191043 |
| | Rapamycin alleviates toxicity of different aggregate-prone proteins | Q45299514 |
| | Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease. | Q47606444 |
| | Novel Vilazodone-Tacrine Hybrids as Potential Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease Accompanied with Depression: Design, Synthesis, and Biological Evaluation | Q47777668 |
| | Assessing nest building in mice | Q48218833 |
| | Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. | Q48306292 |
| | High throughput artificial membrane permeability assay for blood-brain barrier | Q48349894 |
| | Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease | Q48401163 |
| | Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents | Q48556634 |
| | Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease | Q48820847 |
| | Novel Tadalafil Derivatives Ameliorates Scopolamine-Induced Cognitive Impairment in Mice via Inhibition of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5). | Q52607974 |
| | An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. | Q53207278 |
| | Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. | Q53209417 |
| | Nitazoxanide, an anti-parasitic drug, efficiently ameliorates learning and memory impairments in AD model mice | Q89999010 |
| | Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer's Disease Agents | Q90959660 |
| P433 | issue | 4 | |
| P921 | main subject | autophagy | Q288322 |
| P304 | page(s) | 646-666 | |
| P577 | publication date | 2019-07-29 | |
| P1433 | published in | Acta Pharmaceutica Sinica B | Q26854022 |
| P1476 | title | Discovery of nitazoxanide-based derivatives as autophagy activators for the treatment of Alzheimer's disease | |
| P478 | volume | 10 | |